Asset Details
Do you wish to reserve the book?
Discovery and Development of Maraviroc and PF‐232798: CCR5 Antagonists for the Treatment of HIV‐1 Infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Discovery and Development of Maraviroc and PF‐232798: CCR5 Antagonists for the Treatment of HIV‐1 Infection
Do you wish to request the book?
Discovery and Development of Maraviroc and PF‐232798: CCR5 Antagonists for the Treatment of HIV‐1 Infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Book Chapter
Discovery and Development of Maraviroc and PF‐232798: CCR5 Antagonists for the Treatment of HIV‐1 Infection
2011
Overview
This chapter contains sections titled:
Introduction
Discovery of Maraviroc and PF‐232798
HTS and Biological Screening to Guide Medicinal Chemistry
Discovery and Characterization of PF‐232798, A Second‐Generation CCR5 Antagonist
Synthesis
Nonclinical Safety and Toxicity Studies
Phase I‐III Clinical PK Safety and Efficacy Evaluation of Maraviroc
Resistance to Maraviroc in Clinical Trials: Observations and Implications
Future Directions
References
Publisher
John Wiley & Sons, Inc
Subject
ISBN
0470455632, 9780470455630
